RWE supports infliximab biosimilar for treatment of Crohn’s disease

New clinical data will support the use of a biosimilar treatment for Crohn’s disease (CD), and lead to a boost in biosimilar market value, according to GlobalData.

12-month data from the Personalized Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organization (ECCO). PANTS is a three-year prospective study that assessed 1,601 patients with active CD who had received no prior treatment with any anti-tumor necrosis factor drugs. The highly anticipated results demonstrated that Celltrion’s CT-P13 (infliximab biosimilar) is comparable to its reference, Johnson and Johnson’s Remicade (infliximab), as well as AbbVie’s Humira (adalimumab).

Considering the next steps for promoting biosimilar use in the CD market, real-world evidence supporting the switching of the originators to the biosimilars would be essential. According to key opinion leaders, the current use of infliximab biosimilars is mostly restricted to infliximab-naïve patients; the PANTS study also focuses on this patient population. The interviewed gastroenterologists have expressed reluctance in switching a patient who is stable on Remicade to the biosimilar infliximab, due to concerns of the psychological impact on the patient, a situation similar to the use of generics.

Lakshmi Dharmarajan, Associate Director of Immunology at GlobalData, comments: “Given the dearth of head-to-head trial data, this is expected to bolster the use of biosimilars, and lead to cost-effective treatment strategies for patients with CD. Many Key opinion leaders believe that biosimilars are as safe and effective but have emphasized the need for additional clinical data. Therefore, the findings from PANTS will support the use of infliximab biosimilars over the originator brands.”